

XXVIII IFSO World Congress

9-12 September 2025 | Santiago, Chile



Five-year outcomes of conversional one anastomosis gastric bypass after suboptimal response to sleeve gastrectomy or laparoscopic gastric banding

Cornwell, C., Singh, I., & Martin, D. (2025 - Sydney, Australia)

IFSO 2025 Santiago

Combined Therapies, The Dawn of a New Era

ifso2025.org



XXVIII IFSO World Congress

9-12 September 2025
Santiago, Chile

Disclosure Slide


<input checked="" type="checkbox"/>	No, nothing to disclose
<input type="checkbox"/>	Yes, please specify:

<i>Company Name</i>	<i>Honoraria/ Expenses</i>	<i>Consulting/ Advisory Board</i>	<i>Funded Research</i>	<i>Royalties/ Patent</i>	<i>Stock Options</i>	<i>Ownership / Equity Position</i>	<i>Employee</i>	<i>Other (please specify)</i>
Example: company XYZ	X		X		X			

BACKGROUND

1 in 3 Australians obese

1 in 3 Australians overweight



Comorbidities

- Gastro-oesophageal reflux disease
- Dyslipidaemia
- Cardiovascular disease
- Hypertension
- Diabetes mellitus
- Non-alcoholic fatty liver disease
- Gout
- Degenerative joint disease
- Obstructive sleep apnoea
- Depression
- Polycystic ovarian syndrome





XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

OBJECTIVES

One-anastomosis gastric bypass

- Shorter operating time
- Reduced length of stay
- Safe as a primary bariatric surgery



XXVIII IFSO
World Congress



9-12 September 2025
Santiago, Chile

OBJECTIVES

One-anastomosis gastric bypass

- Shorter operating time
- Reduced length of stay
- Safe as a primary bariatric surgery

But is OAGB safe and effective as conversional surgery after weight loss failure?



XXVIII IFSO
World Congress


9-12 September 2025
Santiago, Chile

RESULTS - PATIENT CHARACTERISTICS




XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile





61 prior SG



55 prior LGB

11 prior SB + LGB



n = 127

Preoperative comorbidities:
T2DM (15%)
OSA (19.7%),
Hypertension (27.6%)
Glucose intolerance (14.2%)
Insulin resistance (58.3%)

At conversion,

- Median **age** was **42 years**
- Mean **BMI** was **44.6 kg/m²**
- **79.5%** female

Postoperative complications


- No anastamotic leaks or bleeding
- 4 patients developed reflux requiring **Roux-en-Y GB**
- 1 patient developed a **small bowel obstruction** due to an incisional hernia

OUTCOMES



**XXVIII IFSO
World Congress**

**9-12 September 2025
Santiago, Chile**



	1-year	2-years	5-years
Median EWL	68.1%	63.6%	44.0%
Median TBWL	28.8%	27.8%	20.0%




OUTCOMES

A high percentage (> 90%) of patients achieve $\geq 20\%$ TBWL and $\geq 50\%$ EWL at 12-24 months post conversion.



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile



	1-year	2-years	5-years
Median EWL	68.1%	63.6%	44.0%
Median TBWL	28.8%	27.8%	20.0%

XXVIII IFSO World Congress

9-12 September 2025 | Santiago, Chile



Thank you

IFSO 2025 Santiago

Combined Therapies, The Dawn of a New Era

ifso2025.org